Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Nadia Waheed sold 7,863 shares of the business's stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $71,081.52. Following the sale, the insider owned 318,417 shares in the company, valued at $2,878,489.68. This represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ocular Therapeutix Trading Down 21.3%
Ocular Therapeutix stock opened at $6.99 on Wednesday. Ocular Therapeutix, Inc. has a 52 week low of $5.78 and a 52 week high of $16.44. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -4.85 and a beta of 0.90. The company has a 50 day moving average price of $11.22 and a 200 day moving average price of $11.78.
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. The company had revenue of $13.25 million for the quarter, compared to the consensus estimate of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The company's revenue was down 22.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) EPS. Research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.
Institutional Trading of Ocular Therapeutix
Several large investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC increased its position in Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,242 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 1,392 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in shares of Ocular Therapeutix during the fourth quarter worth $42,000. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix in the fourth quarter valued at about $61,000. Finally, KBC Group NV acquired a new position in Ocular Therapeutix in the fourth quarter valued at about $78,000. Institutional investors own 59.21% of the company's stock.
Ocular Therapeutix News Summary
Here are the key news stories impacting Ocular Therapeutix this week:
- Positive Sentiment: SOL‑1 demonstrated statistical superiority to Regeneron’s Eylea on the trial’s vision endpoint, supporting Ocular’s plan to pursue an FDA filing and a potential new treatment option in wet AMD. Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
- Positive Sentiment: Company and coverage note a clear regulatory path — Ocular is talking about an FDA submission based on the Phase 3 win, which could materially change the company’s product mix if approved. Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
- Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the data readout itself is positive but investors are parsing subgroup/endpoint details and next steps. Ocular Therapeutix releases positive topline results from SOL-1
- Negative Sentiment: Despite the win, shares fell sharply because the observed benefit was characterized as modest and, crucially, the comparator in some analyses was a lower‑dose/less‑favorable version of Eylea — raising questions about clinical meaningfulness and commercial differentiation. Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron's Eylea
- Negative Sentiment: Market and analyst coverage flagged investor skepticism — headlines note a 25–35% intraday decline on heavy volume as traders focused on practical uptake, labeling the result “positive but underwhelming.” Ocular claims a win with eye drug data even as shares sink
- Negative Sentiment: Commentary points to potential regulatory and commercial hurdles (e.g., demonstrating meaningful advantage vs standard‑dose Eylea, pricing/reimbursement, and adoption), which could delay or limit upside even if FDA accepts a filing. Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Regeneron's leading Eylea
Analyst Ratings Changes
Several equities research analysts recently commented on the company. Chardan Capital reissued a "buy" rating and issued a $21.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, December 9th. Citigroup reiterated an "outperform" rating on shares of Ocular Therapeutix in a report on Tuesday. Royal Bank Of Canada restated an "outperform" rating and set a $30.00 price target on shares of Ocular Therapeutix in a research note on Thursday, February 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $20.00 target price on shares of Ocular Therapeutix in a research report on Monday, December 8th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Ocular Therapeutix has a consensus rating of "Moderate Buy" and an average target price of $24.00.
Check Out Our Latest Stock Report on Ocular Therapeutix
Ocular Therapeutix Company Profile
(
Get Free Report)
Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.
The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
